Eptinezumab demonstrates durable efficacy in migraine prevention for patients with multiple prior treatment failures, offering a sustained therapeutic option.
💡 Clinical Impact
- Addresses a critical unmet need by providing sustained migraine prevention for patients refractory to standard therapies.
- Suggests potential for long-term reduction in migraine burden and improved quality of life, which could reduce healthcare utilization.
📊 Evidence Breakdown
- Evidence Grade: 6/10
- Analysis: In participants with migraine having failed 2-4 prior preventive treatments, eptinezumab demonstrated sustained improvements in migraine frequency and disability.
🩺 Practice Recommendation
Consider eptinezumab for patients with migraine refractory to multiple prior preventives, leveraging this emerging data on its long-term durability.